(VIANEWS) – FibroGen (NASDAQ: FGEN) recently witnessed an impressive jump in its stock price over just 21 sessions, rising 33.99% from EUR0.69 to EUR0.93. This increase followed two consecutive sessions of gains for both FibroGen and the NASDAQ index; both experienced 1.11% gains each and marked their fourth consecutive day with growth. Yet even with all this recent growth, FibroGen remains 96.53% below its 52-week high of EUR25.69; its last closing price was EUR0.89.
About FibroGen
FibroGen, founded in 1993, specializes in discovering, developing and marketing therapeutics to address unmet medical needs. FibroGen’s primary product candidates include Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor and currently in Phase III development for treating idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; Roxadustat is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity completed Phase III trials for anemia associated with chronic kidney disease across multiple countries and currently in Phase III development for myelodysplastic syndromes; FifibroGen has established partnerships with Astellas Pharma Inc and AstraZeneca AB; its headquarters are in San Francisco California.
Yearly Analysis
FibroGen stock has fallen significantly in value over the last year; trading currently at EUR0.93 represents an 80% drop compared to its 52-week high of EUR25.69 and higher than its 52-week low of EUR0.33. This indicates a dramatic loss in its worth over this timeframe.
FibroGen is projected to experience a 15.4% sales increase this year and only minimal 0.1% growth next year. Although these numbers represent positive progress, they may not be enough to offset its decrease in stock value.
FibroGen currently boasts an EBITDA ratio of 1.67, which serves as an essential indicator for measuring its financial health. This suggests that FibroGen is producing positive cash flow from its operations – something investors typically take as positive signs.
FibroGen stock may represent an excellent investment opportunity for those who believe its sales growth will continue to outpace any decreases in stock value. Before making their investment decision, investors should conduct extensive research and analysis prior to taking any actions.
Technical Analysis
FibroGen Inc. (NASDAQ: FGEN) has seen its stock price experience an extreme decrease, trading currently at EUR2.87. This figure sits significantly lower than both its 50-day moving average of EUR0.64 and 200-day moving average of EUR5.77; moreover, recent volume (524,540) represents 73.15% less trading activity compared to its typical volume (1,742,100).
FibroGen stock’s volatility was measured with intraday variation averages for last week, month, and quarter of 5.62%, 0.87%, 7.43% respectively; with its highest amplitude being 8.46% during last week; 6.88 % during month; and 7.43 % during quarter.
The stochastic oscillator, an indicator of overbought and oversold conditions, indicates that FibroGen’s stock may currently be considered oversold (=20). This could signal a possible turnaround in its price with investors possibly looking to acquire shares at its current cost.
FibroGen stock has experienced a sharp drop, but its oversold status according to stochastic oscillator could indicate a possible turnaround in price. Investors should exercise caution and conduct further research prior to making any investment decisions.
Quarter Analysis
FibroGen, Inc. (FGEN) is a biotechnology company dedicated to discovering and developing novel treatments for fibrosis, anemia and hypoxia. FGEN reported sales growth estimates of 5.3% for its current quarter and 16.4% for the following one; these numbers correspond with growth estimates of 37.1% and 46.9% respectively for this quarter and the one following it.
FibroGen has demonstrated significant revenue growth with year-on-year quarterly revenue growth of 155.1% and has reported twelve-month trailing revenues totalling 154.98 Million USD.
FibroGen’s revenue growth is driven by its flagship product roxadustat, an anemia treatment for dialysis patients that plays an integral part of its business plan and success is key for FibroGen. Investors should keep this fact in mind.
Overall, FibroGen’s sales growth and revenue growth appear to be on an upward trend, which should provide investors with good news. But investors must take other considerations into account before making investment decisions; such as its financial health, competitive landscape and management team.
Equity Analysis
Earnings Per ShareFibroGen currently boasts an earnings per share figure of $2.45 over its most recent 12-month period, providing further proof of profitability.
More news about FibroGen (FGEN).
